![]() Investigators developed a cost-effectiveness model to estimate the incremental cost per QALY gained when giving lurbinectedin compared with its comparators. Lurbinectedin, a selective inhibitor of oncogenic transcription, received accelerated approval from the FDA in June 202 0 as monotherapy when given at a dose of 3.2 mg/m 2 intravenously (IV) every 21 days for the treatment of patients with metastatic SCLC who have had disease progression on or after platinum-based chemotherapy. The net result is that there is increased apoptosis of cells," Apar Kishor Ganti, MD, MS, University of Nebraska Medical Center, told Targeted Oncology TM. In addition, it can also result in the formation of DNA adducts, DNA double strand breaks and disrupts interactions between DNA and proteins. "Lurbinectedin is an alkaloid that affects RNA transcription. Further, over the past 2 decades, treatments and survival rates for patients with SCLC have not changed much. Despite treatment, the predicted 5-year survival rate is 7% in the United States. When left untreated, the median survival for a patient with SCLC is 2 to 4 months after diagnosis. Lung cancer is the leading cause of cancer death, and SCLC specifically comprises 13% to 15% of all lung cancer diagnoses. These findings still held true under real-world uncertainty, according to probabilistic sensitivity analysis results. The incremental cost-effectiveness ratio (ICER) of lurbinectedin vs the external control arm (ECA) was $20,691/quality-adjusted life year (QALY), which is below the commonly accepted willingness-to-pay (WTP) threshold in the United States of $100,000/QALY. Findings from a cost-effectiveness model found lurbinectedin (Zepzelca) to be a cost-effective second-line treatment option for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy, according to findings presented at the 2023 International Society for Pharmacoeconomics and Outcomes Research (ISPOR)global conference.
0 Comments
Leave a Reply. |